A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects With Atopic Dermatitis
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Roflumilast (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Registrational
- Acronyms INTEGUMENT-OLE
- Sponsors Arcutis Biotherapeutics
- 10 Jun 2024 According to an Arcutis Biotherapeutics media release, Melinda Gooderham is investigator in this trial.
- 10 Jun 2024 Results presented in the Arcutis Biotherapeutics Media Release.
- 31 May 2024 Status changed from active, no longer recruiting to completed.